 Pyridones
"Pyridones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pyridine derivatives with one or more keto groups on the ring.
| Descriptor ID |
D011728
|
| MeSH Number(s) |
D03.383.725.791
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridones".
Below are MeSH descriptors whose meaning is more specific than "Pyridones".
This graph shows the total number of publications written about "Pyridones" by people in UAMS Profiles by year, and whether "Pyridones" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2021 | 2 | 0 | 2 | | 2020 | 2 | 0 | 2 | | 2019 | 0 | 2 | 2 | | 2018 | 0 | 2 | 2 | | 2017 | 1 | 1 | 2 | | 2016 | 2 | 1 | 3 | | 2015 | 2 | 2 | 4 | | 2014 | 2 | 1 | 3 | | 2012 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyridones" by people in Profiles over the past ten years.
-
Cournoyer E, Ferrell J, Sharp S, Ray A, Jordan M, Dandoy C, Grimley M, Roy S, Lorsbach R, Merrow AC, Nelson A, Bartlett A, Picarsic J, Kumar A. Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders. Haematologica. 2024 04 01; 109(4):1137-1148.
-
Stubblefield K, Zahoor S, Sonmezturk H, Haas K, Mattingly D, Abou-Khalil B. Perampanel is effective against Lance-Adams syndrome. Epileptic Disord. 2021 Oct 01; 23(5):769-771.
-
Rech MA, Masic D, Hammond DA. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding. West J Emerg Med. 2021 Feb 26; 22(2):163-169.
-
Ryan KR, Giles F, Morgan GJ. Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma. Eur J Haematol. 2021 Jan; 106(1):90-99.
-
Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 10; 26(10):1564-1568.
-
Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol. 2019 12; 155(3):420-428.
-
Reilly RF, Jain N. Warfarin in nonvalvular atrial fibrillation-Time for a change? Semin Dial. 2019 11; 32(6):520-526.
-
Bavle A, Shah R, Gross N, Gavula T, Ruiz-Elizalde A, Wierenga K, McNall-Knapp R. Encephalocraniocutaneous Lipomatosis. J Pediatr Hematol Oncol. 2018 10; 40(7):553-554.
-
Bhalla V, Abdel-Latif A, Bhalla M, Ziada K, Williams MV, Smyth SS. Meta-Analysis Comparing the Efficacy, Safety, and Cost-Benefit of Direct Acting Oral Anticoagulants Versus Enoxaparin Thromboprophylaxis to Prevent Venous Thromboembolism Among Hospitalized Patients. Am J Cardiol. 2018 10 01; 122(7):1236-1243.
-
Jain N, Reilly RF. Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. Clin J Am Soc Nephrol. 2019 02 07; 14(2):278-287.
-
Smetana KS, Dunne J, Parrott K, Davis GA, Collier ACS, Covell M, Smyth S. Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series. J Thromb Thrombolysis. 2017 Nov; 44(4):519-524.
-
Kaatz S, Mahan CE, Nakhle A, Gunasekaran K, Ali M, Lavender R, Paje DG. Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants. Curr Cardiol Rep. 2017 10 24; 19(12):124.
-
Lee LH, Gasilina A, Roychoudhury J, Clark J, McCormack FX, Pressey J, Grimley MS, Lorsbach R, Ali S, Bailey M, Stephens P, Ross JS, Miller VA, Nassar NN, Kumar AR. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight. 2017 02 09; 2(3):e89473.
-
Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. Cancer Discov. 2017 03; 7(3):302-321.
-
Smith JA, Mayeux PR, Schnellmann RG. Delayed Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Inhibition by Trametinib Attenuates Systemic Inflammatory Responses and Multiple Organ Injury in Murine Sepsis. Crit Care Med. 2016 08; 44(8):e711-20.
-
Del Campo JM, Birrer M, Davis C, Fujiwara K, Gollerkeri A, Gore M, Houk B, Lau S, Poveda A, Gonz?lez-Mart?n A, Muller C, Muro K, Pierce K, Suzuki M, Vermette J, Oza A. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecol Oncol. 2016 Jul; 142(1):62-69.
-
Shah A, Shewale A, Hayes CJ, Martin BC. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2016 06; 47(6):1555-61.
-
Dohare P, Zia MT, Ahmed E, Ahmed A, Yadala V, Schober AL, Ortega JA, Kayton R, Ungvari Z, Mongin AA, Ballabh P. AMPA-Kainate Receptor Inhibition Promotes Neurologic Recovery in Premature Rabbits with Intraventricular Hemorrhage. J Neurosci. 2016 Mar 16; 36(11):3363-77.
-
Bose C, Megyesi JK, Shah SV, Hiatt KM, Hall KA, Karaduta O, Swaminathan S. Evidence Suggesting a Role of Iron in a Mouse Model of Nephrogenic Systemic Fibrosis. PLoS One. 2015; 10(8):e0136563.
-
Spiller HA, Mowry JB, Aleguas A, Griffith JR, Goetz R, Ryan ML, Bangh S, Klein-Schwartz W, Schaeffer S, Casavant MJ. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers. Ann Emerg Med. 2016 Feb; 67(2):189-95.
-
Heuck CJ, Jethava Y, Khan R, van Rhee F, Zangari M, Chavan S, Robbins K, Miller SE, Matin A, Mohan M, Ali SM, Stephens PJ, Ross JS, Miller VA, Davies F, Barlogie B, Morgan G. Inhibiting MEK in MAPK pathway-activated myeloma. Leukemia. 2016 Apr; 30(4):976-80.
-
Bagchi RA, Mozolevska V, Abrenica B, Czubryt MP. Development of a high throughput luciferase reporter gene system for screening activators and repressors of human collagen Ia2 gene expression. Can J Physiol Pharmacol. 2015 Oct; 93(10):887-92.
-
Pinto C, Samuel BP, Ratnasamy C, Vettukattil JJ. Thrombosis in Fontan patient on apixaban. Int J Cardiol. 2015 Mar 01; 182:66-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|